Mechanisms and clinical management of inherited channelopathies: long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome.
about
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Afford New Opportunities in Inherited Cardiovascular Disease ModelingMechanisms of ventricular arrhythmias: from molecular fluctuations to electrical turbulenceTwo novel Brugada syndrome-associated mutations increase KV4.3 membrane expression and functionFever-induced QTc prolongation and ventricular fibrillation in a healthy young man.Cardiac syncope.Current and emerging antiarrhythmic drug therapy for ventricular tachycardiaPerceptions of an implantable cardioverter-defibrillator: A qualitative study of families with a history of sudden life-threatening cardiac events and recommendations to improve care.Early identification of risk factors for sudden cardiac death.Common variants in CASQ2, GPD1L, and NOS1AP are significantly associated with risk of sudden death in patients with coronary artery disease.Genetics for the general internistDantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia.Cardiac ion channelopathies and the sudden infant death syndromeGene therapy for ventricular tachyarrhythmias.In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells.Potassium channel activators differentially modulate the effect of sodium channel blockade on cardiac conduction.Arrhythmias and vagus nerve stimulation.Causes of sudden cardiac arrest in young athletes.Pharmacotherapy to reduce arrhythmic mortality.Cardiac sodium channels and inherited electrophysiological disorders: an update on the pharmacotherapy.The Hearts of Heroes: the epidemiology of cardiac disease in the UK Armed Forces.Advances in the pharmacologic treatment of ventricular arrhythmias.Antiarrhythmic Action of Flecainide in Polymorphic Ventricular Arrhythmias Caused by a Gain-of-Function Mutation in the Nav 1.5 Sodium Channel.Sudden cardiac death: focus on the genetics of channelopathies and cardiomyopathies.Electrocardiogram with a twist.Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement.Screening for, and management of, possible arrhythmogenic syndromes (channelopathies/ion channel diseases).Gender Issues in Medical Decisions: Implicit Stereotyping and Unconscious Bias.EHRA/HRS/APHRS expert consensus on ventricular arrhythmiasEHRA/HRS/APHRS expert consensus on ventricular arrhythmiasThe Medical Management of Pediatric Arrhythmias
P2860
Q26750618-F2DA4B1D-44DD-457E-ABF6-AE341791EB2CQ27009543-958C4828-99AA-43D8-9429-A79F36DE0BAAQ28115722-A6DF9D88-298A-4F94-80EA-D14F4E97DE3FQ30472835-FCEE7FD7-58C1-4F16-8DA9-A34951891820Q33162027-4267CA47-3940-43E5-BC8B-623E7D9AC7C3Q33936131-DC8F9DA3-1E87-4303-A850-223ED8FC76A2Q34463807-326EB9DE-F7B7-4903-BA9C-21547715125EQ34640857-F1181991-B451-485E-AEE1-809AF8A4F661Q35177170-C00313F6-D218-4AA5-90E5-99EA417A3571Q35634020-B0486B20-FCDB-4FE8-A343-0D038DEEB266Q36037969-0DC6D48C-2A91-4592-A5CE-B975B142E1B3Q36486478-0C0B7369-4881-4F82-B2DD-A01A68283BF8Q36726175-5489638D-E16C-43EE-8412-00FB292EACBCQ37005193-994C1BD7-DBB6-4110-AB6C-6FAA2C60FB10Q37693351-1EA080AB-CAB4-4D3E-8BFB-C605011E3082Q37766114-5FDE9342-A8F8-4C83-8E2A-478C1F61CC39Q37777011-CA1543EF-A6EE-467A-9E82-B16A2303D6E0Q38191066-A3CA2A37-791D-41D1-9876-67F167C4DDF9Q38225937-120A7A49-9AF0-4AC5-8518-E7A299D9BF9EQ38561089-4CCA7D5D-468A-4EFC-9B46-34176460C0C6Q38619253-708FB11F-4D6B-4651-AEF9-0BD52FC3C094Q39930559-5D360BE6-A425-4E11-B60E-B725B9593A68Q41392147-5B78CFA8-0DA1-4B67-A2B4-6AF08A344D33Q41789698-F1EAF223-F4DF-407B-BF31-E7413EECC353Q46269501-6D2357A3-EDBB-4C06-9EC2-B4F2BABF616CQ46290258-95B6C374-DA9D-4B54-97C2-EB5E85738E63Q55129619-EE81CB1D-B442-48ED-80D8-BFF02F417AD8Q57626635-EF6BB8D6-0EB3-49D7-A11B-2A511050B92DQ57626770-51075F51-B8D2-460B-B479-F5A0541CC242Q59200867-88E349C2-D174-4FFC-BFE9-A33D21A2B8F0
P2860
Mechanisms and clinical management of inherited channelopathies: long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Mechanisms and clinical manage ...... cardia, and short QT syndrome.
@ast
Mechanisms and clinical manage ...... cardia, and short QT syndrome.
@en
type
label
Mechanisms and clinical manage ...... cardia, and short QT syndrome.
@ast
Mechanisms and clinical manage ...... cardia, and short QT syndrome.
@en
prefLabel
Mechanisms and clinical manage ...... cardia, and short QT syndrome.
@ast
Mechanisms and clinical manage ...... cardia, and short QT syndrome.
@en
P921
P1433
P1476
Mechanisms and clinical manage ...... cardia, and short QT syndrome.
@en
P2093
Elizabeth S Kaufman
P356
10.1016/J.HRTHM.2009.02.009
P433
P577
2009-02-12T00:00:00Z